PIA
RXRX icon

Powell Investment Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Powell Investment Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$94.2K Buy
30,696
+1,000
+3% +$3.86K 0.03% 152
2025
Q4 		$121K Buy
29,696
+18,089
+156% +$89.6K 0.04% 145
2025
Q3 		$56.6K Sell
11,607
-8,423
-42% -$44.2K 0.02% 157
2025
Q2 		$101K Buy
+20,030
New +$98.4K 0.04% 142

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Powell Investment Advisors's RXRX Position: Q1 2026 in Review

Powell Investment Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 3.4% in Q1 2026, buying an estimated $3.86K and bringing the position to 30,696 shares worth $94.2K. The position accounts for 0.03% of the portfolio, ranked #152.

Powell Investment Advisors first reported a position in RXRX in Q2 2025 and has held it in 4 quarters since. The position peaked at $121K in Q4 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Powell Investment Advisors held 30,696 shares of Recursion Pharmaceuticals worth $94.2K as of Q1 2026.
  • Powell Investment Advisors bought 1,000 Recursion Pharmaceuticals shares in Q1 2026, an estimated $3.86K.
  • Recursion Pharmaceuticals made up 0.03% of Powell Investment Advisors's portfolio in Q1 2026, its #152 holding.
  • Powell Investment Advisors first reported a position in Recursion Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Powell Investment Advisors's Recursion Pharmaceuticals position peaked at $121K in Q4 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Powell Investment Advisors's 13F filing for Q1 2026, filed 23 Apr 2026.